TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06694532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringes
Description: Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringes
Description: Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .
Study: NCT06687057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback Training
Description: The intervention involves 5 training sessions lasting 45 minutes (specifically, 5-minute baseline and 5 HRV biofeedback trials lasting 5 minutes each) according to the protocol published by Lehrer et al. (2013). Physiological signals (ECG and respiratory rate) will be recorded during all sessions. During the training, participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing. They will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle in order to maximize the difference between the maximum and minimum heart rate within each respiratory cycle \[i.e., respiratory sinus arrhythmia (RSA), an index of vagal modulation on the heart\] (Lehrer et al., 2003; Lehrer et al., 2000).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: The Placebo procedure requires participants to attend 5 sessions lasting 45 minutes during which they perform a task. Physiological signals (ECG and respiration rate) will be recorded during all sessions. Participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing but these will not directly reflect the subject's cardiorespiratory activity. Participants in the control group will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle, but the feedback on the screen will not reflect that subject's RSA changes.
Study: NCT06703190

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
Description: Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2

Intervention type: BIOLOGICAL
Intervention: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
Description: The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.

Intervention type: BIOLOGICAL
Intervention: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
Description: The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.
Study: NCT06709248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Coping Program
Description: The Life Coping Program is built around a coordinated 5-day Life Coping Course. Participants included are grouped by their primary condition, meaning the diagnosis or illness reasoning the referral. Each family is assigned a dedicated Primary Contact throughout the program, and the program consists of three phases: Phase 1: Preparation - Written/visual materials and questionnaires are provided to motivate and inform. A digital consultation occurs 3-5 weeks before the Life Coping Course, covering goals, commitment, and follow-up. Materials are offered in paper or digital formats. Phase 2: Life Coping Course - The 5-day course includes individual consultations, group activities, education, and medical follow-ups, focusing on coping strategies and well-being. Phase 3: Implementation - A summary meeting is conducted, including key persons for further implementation in own local area. Digital follow-ups at 3-4 weeks and 6 months post course assess progress and guide goal achievement.
Study: NCT06723522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS
Description: 2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days, each stimulation lasted for 20 min, with 30 s of ramp-up and ramp-down before and after the 20-min stimulation, respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Received 1 min of ramping up/down without experiencing 2 mA HD-tDCS stimulation lasted for 20 min.
Study: NCT06732830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DayDrop Advanced ophthalmic drop
Description: The patient will administer 1 or 2 drops of DayDrop Advanced in each eye 3 times a day for 3 months.
Study: NCT06736366

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement - Active comparator
Description: Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement - Experimental product
Description: Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10
Study: NCT06737289

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical Guide
Description: Placing extralarge implats for rahabilitation atrophic maxilla

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Guide
Description: Placing extralarge implats for rahabilitation atrophic maxilla
Study: NCT06739330

Intervention type: DEVICE
Intervention: Fibroscan
Description: Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.

Intervention type: DEVICE
Intervention: Fibroscan
Description: Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
Study: NCT06739239

Intervention type: DEVICE
Intervention: Extra-Vascular Implantable Cardioverter Defibrillator
Description: The pulse generator is implanted along the patient's left midaxillary line, and the lead is positioned substernally.
Study: NCT06739096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Wave Diathermy
Description: Shortwave diathermy (SWT) is a form of electromagnetic therapy that causes the movement of ions, the disruption of molecules, and the generation of eddy currents, which ultimately produce heat in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: range of motion, strengthening and stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: range of motion, strengthening and stretching exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Short Wave Diathermy
Description: Sham protocol
Study: NCT06740552

Intervention type: DRUG
Intervention: Evolocumab
Description: Evolocumab 140mg every two weeks

Intervention type: DRUG
Intervention: Lipid Lowering Medication
Description: Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
Study: NCT06745050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message mHealth Evidence-based intervention
Description: MM! includes three messages per week in month one, then two messages per week for the six-month intervention period. Earlier messages include more informational and motivational content, while later messages include more behavioral skills.
Study: NCT06744218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patients who will be assigned to the control group and subjected to standard treatment (usual care at our clinic) will undergo a physiotherapy treatment of 8 in-person sessions for 4 post-operative weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Treatment
Description: patients who will be assigned to the experimental group and subjected to the experimental treatment will undergo a physiotherapy treatment of 8 sessions in telerehabilitation for 4 post-operative weeks
Study: NCT06744296

Intervention type: OTHER
Intervention: Blood Draws and Tissue Sample(s)
Description: All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.

Intervention type: OTHER
Intervention: Blood Draws and Tissue Sample(s)
Description: All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.
Study: NCT06745726

Intervention type: DRUG
Intervention: Zestril
Description: N/A, this is an observational study.
Study: NCT06745583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EI-1071 tablet, oral
Description: Dose: 448.2 mg BID for 28 days
Study: NCT05319587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
Study: NCT06686823

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: n informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Program
Description: The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
Study: NCT06686680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy (ESWT)
Description: Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
Study: NCT06686381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximum TURBT
Description: Total removal of the bladder tumor through TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximum TURBT
Description: Total removal of the bladder tumor through TURBT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Immunotherapy Induction
Description: Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Immunotherapy Induction
Description: Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy: 20 fractions, 55 Grays

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy: 20 fractions, 55 Grays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy Maintenance
Description: Maintenance Avelumab every 2 weeks for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchful waiting with supportive care
Description: 1 year watch and wait
Study: NCT06690619

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 315 mg Alpha-GPC
Description: 350 mg of 90% pure alpha-GPC (315 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 630 mg Alpha-GPC
Description: 700 mg of 90% pure alpha-GPC (630 mg)
Study: NCT06689306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7E learning model
Description: 7E learning model7E learning cycle is a teaching model that encourages students to be active, to think about the findings they obtain, to interpret their findings according to their initial plans and to predict them in new situations. This model provides students with opportunities for discussion and interaction. The model is designed based on constructivist theory. The guiding concept of constructivism is that later learning is greatly influenced by previous knowledge; therefore, learning should be based on the interaction of old and new knowledge. 7E learning cycle model consists of seven steps: Reveal, Participate, Explore, Explain, Elaborate, Evaluate and Extend. According to past studies, 7E model is more effective in developing students than traditional learning models.
Study: NCT06504082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
Study: NCT06691815

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Triptorelin (GnRH agonists)
Description: 1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)
Study: NCT06690697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: 200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: 200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: 5 mg, po, bid, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: 5 mg, po, bid, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 0.4 g, po, bid, each 21 days as a treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 0.4 g, po, bid, each 21 days as a treatment cycle
Study: NCT06300619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates+4
Description: 12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
Study: NCT06694740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma 1-b
Description: interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Study: NCT06300619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: 12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
Study: NCT06695338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Bone Regeneration (Submerged)
Description: Guided Bone Regeneration by means of bone xenograft and collagen membrane (submerged approach)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (Non-submerged)
Description: Guided Bone Regeneration by means of bone xenograft and collagen membrane (Non submerged Approach)
Study: NCT06695611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increase systolic blood pressure
Description: To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase systolic blood pressure
Description: To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decrease systolic blood pressure
Description: To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease systolic blood pressure
Description: To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight